Amgen Inc.'s multiple myeloma pipeline received a needed boost on 13 September when the company reported that its proteasome inhibitor Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson/Genmab AS's Darzalex (daratumumab) reduced the risk of death in relapsed or refractory patients following one to three prior lines of treatment.
The company's stock closed 0.8% higher at $195.47 per share after it reported results from the Phase III CANDOR clinical...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)